Time filter

Source Type

Skowronski D.M.,British Columbia Center for Disease Control | Skowronski D.M.,University of British Columbia | Janjua N.Z.,British Columbia Center for Disease Control | Janjua N.Z.,University of British Columbia | And 23 more authors.
Journal of Infectious Diseases

Background Cases of infection due to a novel swine-origin variant of influenza A virus subtype H3N2 (H3N2v) have recently been identified in the United States, primarily among children. We estimate levels of cross-reactive antibody to H3N2v by age and assess whether seasonal trivalent inactivated influenza vaccine (TIV), with or without adjuvant, may increase seroprotection.Methods Antibody to H3N2v was assessed by hemagglutination inhibition (HI) assay and, for a subset, also by microneutralization assay. Seroprevalence and seroprotection were defined as an HI titer of ≥40, and levels were compared with those for ancestral and contemporary human strains. The analysis included 1116 sera collected during fall 2010, corresponding to approximately 100 sera per decade of life. Vaccine-induced antibody levels were also assessed in sera from 136 children aged <10 years and 65 adults aged 20-59 years before and after receipt of 2010-2011 split TIV and in sera from 182 elderly individuals aged ≥65 years before and after receipt of 2011-2012 split TIV (for 31 individuals), MF59-adjuvanted TIV (for 72), or unadjuvanted subunit TIV (for 79).Results The overall prevalence of HI titers of ≥40 against A(H3N2)v was 25% . No children aged <5 years and <20% of individuals aged ≤14 years or ≥40 years had an HI titer of ≥40. Conversely, among individuals aged 15-39 years, half of teens and adults showed H3N2v seroprotection. Following TIV receipt, <15% of individuals in any vaccine group developed a 4-fold increase in antibody level.Conclusions A substantial proportion of adolescents and young adults have cross-reactive antibody against emerging H3N2v, whereas children and older adults show broad susceptibility. Recent formulations of TIV do not substantially increase seroprotection. A specific vaccine would be needed if H3N2v establishes epidemic spread.Clinical Trials Registration NCT01140009 and NCT01368796. © 2012 The Author. Source

Ming D.S.,BC Biomedical Laboratories | Heathcote J.,BC Biomedical Laboratories | Garg A.,BC Biomedical Laboratories | Darbyshire J.,BC Biomedical Laboratories | And 2 more authors.

Background: To develop an UPLC-MS/MS method to replace the in-house immunoassay for the analysis of urinary cortisol. Results: Cortisol was extracted from human urine by ethyl acetate and analyzed on a Waters ACQUITY TQD system using a BEH C18 column. Linear calibration curves were generated over the range of 27.6 to 1380 nmol/l and exhibited consistent linearity and reproducibility with a correlation coefficient greater than 0.9950. Intra-day coefficients of variation were between 3.74 and 5.10% and inter-day coefficients of variations were between 4.22 and 6.73%. The extraction recovery of cortisol was greater than 83%. Conclusion: An accurate, rapid and robust UPLC-MS/MS method for the determination of urinary cortisol has been developed and validated. With a lower flow rate (0.4 ml/min), a shorter running time per sample and a simple and cost-effective sample preparation, this method is a desirable option for clinical laboratories. © 2011 Future Science Ltd. Source

Discover hidden collaborations